Jul. 30 at 5:40 PM
$ALNY hey dip buyers… there’s zero point. Buying doesn’t make the stock go up and selling doesn’t make it go down. Rerate is determined by the fake mm’s, but also, go and tell Stat News and AF in particular to fuck off. Their little darling that was a “sleep well at night” investment in the mid-high
$400’s has one franchise… with competition. What happened to their top 5 most valuable big pharma goal? Sorry, but they squandered an opportunity to acquire or invest in some competition and haven’t really made much progress on their pipeline, speaking of which, how’s their extra-hepatic stuff doing? Nothing on subq CNS. Respect to ALNY for getting the first RNAi assets across the finish line and pioneering the field, but Arrowhead will be the most valuable company in this space if they don’t get acquired first. Mark it.
$ARWR
